GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (LTS:0K3W) » Definitions » Cyclically Adjusted FCF per Share

Myriad Genetics (LTS:0K3W) Cyclically Adjusted FCF per Share : $0.58 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Myriad Genetics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Myriad Genetics's adjusted free cash flow per share for the three months ended in Mar. 2024 was $-0.303. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.58 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Myriad Genetics's average Cyclically Adjusted FCF Growth Rate was -46.20% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -29.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -17.90% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 2.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Myriad Genetics was 210.70% per year. The lowest was -29.40% per year. And the median was 16.00% per year.

As of today (2024-06-06), Myriad Genetics's current stock price is $22.705. Myriad Genetics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $0.58. Myriad Genetics's Cyclically Adjusted Price-to-FCF of today is 39.15.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Myriad Genetics was 55.18. The lowest was 6.29. And the median was 19.82.


Myriad Genetics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Myriad Genetics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Cyclically Adjusted FCF per Share Chart

Myriad Genetics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.45 4.30 1.63 1.10 0.62

Myriad Genetics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.04 0.95 0.76 0.62 0.58

Competitive Comparison of Myriad Genetics's Cyclically Adjusted FCF per Share

For the Diagnostics & Research subindustry, Myriad Genetics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myriad Genetics's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Cyclically Adjusted Price-to-FCF falls into.



Myriad Genetics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Myriad Genetics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.303/131.7762*131.7762
=-0.303

Current CPI (Mar. 2024) = 131.7762.

Myriad Genetics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.466 100.560 0.611
201409 -0.059 100.428 -0.077
201412 0.618 99.070 0.822
201503 0.345 99.621 0.456
201506 0.674 100.684 0.882
201509 0.399 100.392 0.524
201512 0.691 99.792 0.912
201603 0.615 100.470 0.807
201606 0.491 101.688 0.636
201609 -0.064 101.861 -0.083
201612 0.425 101.863 0.550
201703 0.580 102.862 0.743
201706 0.515 103.349 0.657
201709 0.311 104.136 0.394
201712 0.430 104.011 0.545
201803 0.119 105.290 0.149
201806 0.632 106.317 0.783
201809 0.089 106.507 0.110
201812 0.458 105.998 0.569
201903 0.047 107.251 0.058
201906 0.402 108.070 0.490
201909 0.195 108.329 0.237
201912 -0.071 108.420 -0.086
202003 0.185 108.902 0.224
202006 0.370 108.767 0.448
202009 -0.814 109.815 -0.977
202012 -0.277 109.897 -0.332
202103 0.851 111.754 1.003
202106 -0.115 114.631 -0.132
202109 -0.519 115.734 -0.591
202112 -0.161 117.630 -0.180
202203 -0.659 121.301 -0.716
202206 -0.701 125.017 -0.739
202209 -0.254 125.227 -0.267
202212 -0.270 125.222 -0.284
202303 -0.697 127.348 -0.721
202306 -0.241 128.729 -0.247
202309 -0.484 129.860 -0.491
202312 -0.789 129.419 -0.803
202403 -0.303 131.776 -0.303

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Myriad Genetics  (LTS:0K3W) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Myriad Genetics's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=22.705/0.58
=39.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Myriad Genetics was 55.18. The lowest was 6.29. And the median was 19.82.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Myriad Genetics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Myriad Genetics (LTS:0K3W) Business Description

Traded in Other Exchanges
Address
320 Wakara Way, Salt Lake City, UT, USA, 84108
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Myriad Genetics (LTS:0K3W) Headlines

No Headlines